Clinical Trials Logo

Anal Canal Cloacogenic Carcinoma clinical trials

View clinical trials related to Anal Canal Cloacogenic Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03233711 Active, not recruiting - Clinical trials for Anal Canal Cloacogenic Carcinoma

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Start date: July 5, 2018
Phase: Phase 3
Study type: Interventional

This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02560298 Active, not recruiting - Clinical trials for Anal Squamous Cell Carcinoma

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

InterAACT
Start date: August 23, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin and fluorouracil are more effective than carboplatin and paclitaxel in treating anal cancer.